Company Overview and News
Vistra Energy Corp. (VST - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $19.68–$21.13 in the past one-month time frame, witnessed a sharp increase yesterday.
VST UNP DYNC DYN.WS DYN VST.WSA CNP DYN.WSA VSTE DYN-A HEAR DYN.PRA
Chicago, IL – April 10, 2018 - Stocks in this week’s article Weight Watchers International, Inc. (WTW - Free Report) , Match Group, Inc. (MTCH - Free Report) , Dynegy Inc. and HFF, Inc. (HF - Free Report) .
CBSH CBSHP UNP DYNC SBSI HDS DYN.WS WTW DYN CBCB ACIIQ MTCH ACI DYN.WSA DYN-A ARCH DYN.PRA
When value or growth investing fails to fetch sustained profits, one should explore another time-tested winning strategy that simply bets on the frontrunner stocks. Translated, one of the most successful strategies today is to get in on momentum stocks at the right time.
MTCH DYNC DYN-A DYN.WSA DYN.WS WTW DYN DYN.PRA
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000.
VEC GFN GFNCP DYNC ADP ADP DYN.WS DYN GFNSL ACIIQ ACI ADPVV VIRT DYN.WSA DYN-A ARCH GFDV DYN.PRA
Eversource Energy (ES - Free Report) has gained 1.0% in the last ten days compared with its industry's gain of 0.1%. The company pursues organic growth as well as strategic acquisitions to expand its operations. It is currently focused on upgrading its distribution and utility transmission infrastructure. The company has plans to invest $10.8 billion in the 2018-2021 time period.
DYNC MS.PRE MS.PRF DYN.WS MS.PRG PNW DYN MS.PRA ES MS.PRI MS.PRK CNP DYN.WSA DYN-A MS DYN.PRA
Dynegy Inc. (DYN - Free Report) hit a new 52-week high of $13.58 before closing the session a bit lower at $13.38 on Mar 9. Year to date, the stock has delivered an impressive return of about 79.4% compared with the S&P 500 index’s rally of 17.8%. Over the past 52 weeks, Dynegy’s shares have ranged from a low of $5.84 to a high of $13.58. Average volume of shares traded over the last three months is approximately 3.
VST DYNC DYN.WS DYN NEE.PRI NEE.PRJ NEE.PRC CNP DYN.WSA VSTE DYN-A NEE.PRQ NEE.PRR NEE DYN.PRA
Investors in Dynegy Inc. (DYN - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 16, 2018 $9.00 Callhad some of the highest implied volatility of all equity options today.
NTLA DYNC UZA DYN.WS DYN UZC UZB HIMX GJH DYN.WSA DYN-A USM DYN.PRA
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to DYNC / Dynegy Inc. on message board site Silicon Investor.
|Dyncore formerly Daapoint|
as of ET